Table 2. Number and severity of adverse... | Rockefeller University Press

Table 2.

Number and severity of adverse events

	SOC (n = 21)			Im + SOC (n = 20)
Adverse event	Patients numbers with severity ≥1	Average severity score	Imatinib related	Patients numbers with severity ≥1	Average severity score	Imatinib related
Itching/skin reaction/rash	0 (0%)	0 (0; 0–0)	NA	0 (0%)	0 (0; 0–0)	NA
Edema	0 (0%)	0 (0; 0–0)	NA	0 (0%)	0 (0; 0–0)	NA
Fever	21 (100%)	2.4 (0.74; 1–3)	NA	20 (100%)	2.2 (0.67; 1–3)	0 (0; 0–0)
Headache	4 (19.0%)	0.2 (0.40; 0–1)	NA	3 (15.0%)	0.2 (0.37; 0–1)	0 (0; 0–0)
Body aches/pain	0 (0%)	0 (0; 0–0)	NA	0 (0%)	0 (0; 0–0)	NA
Nausea	0 (0%)	0 (0; 0–0)	NA	1 (5.0%)	0.05 (0.22; 0–1)	0 (0; 0–0)
Vomiting	0 (0%)	0 (0; 0–0)	NA	0 (0%)	0 (0; 0–0)	NA
Diarrhea	2 (9.5%)	0.10 (0.30; 0–1)	NA	2 (10.0%)	0.10 (0.31; 0–1)	0 (0; 0–0)
Anemia	2 (9.5%)	0.10 (0.30; 0–1)	NA	1 (10.0%)	0.05 (0.22; 0–1)	0 (0; 0–0)
Jaundice	1 (4.8%)	0.05 (0.22; 0–1)	NA	0 (0%)	0 (0; 0–0)	NA

	SOC (n = 21)			Im + SOC (n = 20)
Adverse event	Patients numbers with severity ≥1	Average severity score	Imatinib related	Patients numbers with severity ≥1	Average severity score	Imatinib related
Itching/skin reaction/rash	0 (0%)	0 (0; 0–0)	NA	0 (0%)	0 (0; 0–0)	NA
Edema	0 (0%)	0 (0; 0–0)	NA	0 (0%)	0 (0; 0–0)	NA
Fever	21 (100%)	2.4 (0.74; 1–3)	NA	20 (100%)	2.2 (0.67; 1–3)	0 (0; 0–0)
Headache	4 (19.0%)	0.2 (0.40; 0–1)	NA	3 (15.0%)	0.2 (0.37; 0–1)	0 (0; 0–0)
Body aches/pain	0 (0%)	0 (0; 0–0)	NA	0 (0%)	0 (0; 0–0)	NA
Nausea	0 (0%)	0 (0; 0–0)	NA	1 (5.0%)	0.05 (0.22; 0–1)	0 (0; 0–0)
Vomiting	0 (0%)	0 (0; 0–0)	NA	0 (0%)	0 (0; 0–0)	NA
Diarrhea	2 (9.5%)	0.10 (0.30; 0–1)	NA	2 (10.0%)	0.10 (0.31; 0–1)	0 (0; 0–0)
Anemia	2 (9.5%)	0.10 (0.30; 0–1)	NA	1 (10.0%)	0.05 (0.22; 0–1)	0 (0; 0–0)
Jaundice	1 (4.8%)	0.05 (0.22; 0–1)	NA	0 (0%)	0 (0; 0–0)	NA

Data are presented as n (%) or mean (SD; range). Severity score of 0, 1, 2, and 3 represent normal, mild, moderate, and severe, respectively (see Table S3 for additional information). NA, not applicable.